학술논문
EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
Document Type
Abstract
Author
Source
In Value in Health December 2022 25(12) Supplement:S168-S168
Subject
Language
ISSN
1098-3015